REDWOOD CITY, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended June 30, 2025 and provided a corporate update.
Related Questions
What potential catalysts or headwinds should traders monitor that could drive the stock price in the short to medium term?
What were Jasper Therapeutics' actual revenue and earnings figures for Q2 2025, and how do they compare to analyst expectations?
Did the company provide any guidance for future sales or milestones related to briquilimab?
How did the reported results impact the company's cash runway and need for additional financing?
What is the current status of the clinical trials for briquilimab in CSU, CIndU, and asthma, and are there any upcoming data readouts?
Are there any updates on regulatory interactions with the FDA or other health authorities for briquilimab approvals?
How does the valuation of Jasper Therapeutics compare to peers developing c‑Kit targeted therapies or other mast cell disease treatments?
Did the corporate update reveal any new partnership, licensing, or acquisition activities that could affect the company's growth prospects?
What is the market's perception of the risk/reward profile for investing in Jasper Therapeutics based on this earnings release?
Are there any changes in the company's capital structure, such as share issuances or stock option grants, that could dilute existing shareholders?